Journal of Oral Medicine and Pain

Korean Academy of Orofacial Pain and Oral Medicine (대한안면통증구강내과학회)
권호 표지

Influence of Botulinum Toxin A Injection on the Electromyographic Activity of Masseter Muscle

보툴리눔 A형 독소 주사가 교근의 근전도에 미치는 영향

Kim, Han-Seok;Kim, Ki-Seo;Kim, Seong-Taek;Choi, Jong-Hoon
김한석;김기서;김성택;최종훈

  • Published : 20041200
⟨ Previous Next ⟩

Abstract

23 applicants were randomly divided into 3 groups(A, B, C) In group A, 25 unit of BTX -A was unilaterally Injected into masseter muscle(bilaterally 50 unit) and in group B, 35 unit was unilaterally injected(bilaterally 70 unit) In group C, controlled group, normal saline was injected. In each of them, EMG was examined before Injection and 2weeks, 4weeks, 8weeks, 12weeks, 24 weeks after Injection. The changes of EMG value was Insighted by elapsed time in each group, and at each time, the differences of th change of EMG value was also Investigated among the groups Then these results were analysed statistically. The conclusions of this study were followings: 1. In two groups with BTX-A Injection, EMG activity of masseter muscles was reduced and It was suddenly reduced within 2weeks after injection. 2. From 8weeks after Injection, EMG activity of masseter muscles began to rebound, but at 24 weeks after injection, was still lower than that of pre-injection. 3. More reduction was not occurred In the group B than In the group A and therapeutic effect also was not maintained longer In the group B than In the group A In addition, rebound of EMG value was more In group 13 than 10 group A. 4. Even though EMG activity of masseter muscle was reduced, there was no change In the EMG activity of temporal muscle.

총 23 명의 지원지를 무작위적으로 A, B, C, 3개의 집단으로 구분하여 A집단에는 양측 교근에 각각 25단위의 독소를 주사하였고 B집단에는 각각 35단위의 독소를 주사하였다 C집단은 대조군으로 생리 식염수를 주사하였다. 각각의 집단에서 주사 전과 주사 후 2주, 4주, 8주, 12주, 24 주에 걸쳐 교근의 친층과 전방 측두근에서 근전도를 측정하여 시간의 경과에 따른 근전도 값의 변화와 독소의 사용량에 따른 근전도 값의 변화의 차이를 조사하였다. 본 연구의 결과는 다음과 같다. 1. BTX-A를 주사한 두 집단에서는 주사 후 교근에서 근전도의 활성의 감소를 보였으며 주사 후 약 2주경까지 급격히 감소하였다. 2. 감소된 교근의 근전도는 주사 후 약 8 주부터 회귀를 보였으며 24주가 경과한 후에도 주사 전과 비교하여 100%의 회귀를 보이지는 않았다. 3. 35단위를 사용했던 집단이 25단위를 사용하였던 집단에 비해서 치료 지속시간이 길어지거나 근전도 값이 더 많이 감소되지는 않았으며, 오히려 24주가 경과한 후 희귀병은 35단위를 사용했던 집단에서 더 컸다. 4. 주사 후 교근의 휠성 감소에 따른 측두근의 보상성 근진도 활성 증가는 보이지 않았다.

Keywords

References

  1. Bnn MF Botulinum LOXln cherrusuy, pharmacology, tOXICIty, and nnmunology Muscle nerve Suppl 1997,65116 168
  2. Freund B, Schwartz M, SynungLon]M The usc of botuhnum tOXIn for the treatment of temporoman dtbular disorder prelmunary fmdmgs J Oral Maxillofac Surg J999,57(8) 916~920
  3. Mellmg J, Hambleton P, Shone CC Clostridium botuhnum toxms nature and preparation for chrucal use Eye 1988,2(Ptl) 16 23
  4. Johnson E1\ Clostndtal toxins as therapeuuc agents benefits of nature's most tOXiC proteins 1\nnu Rev Microlnol 1999.53 551 ~575
  5. Scott J\B Botulmum toxm mjection of eye muscles to correct strabismus Trans Am Ophrhalrnol Soc 1981.797'34 770
  6. Iankovic J Dotulmum 1\ toxin m the treatment of blepharospasm i\dv Ncurol 1988,49 467~472
  7. jitpimolmard S, Tiamkao S, Laopaiboon TvI Long term results of botulmum toxm type A (Dysport) In the treatment of hemifacial spasm a report of 175 cases J Neurol Neurosurg I'svclnatrv 199B,64(6) 751-757
  8. Dutton JJ Dotulmum 1\ toxm m the treatment of cramocervica. muscle spasm short and long -term, local and systemic effects Surv Ophthalmol 1996,410):31-65
  9. Cclb DJ, Lowenstein DIl, Ammoff M] Controlled tnal of botulmum tOXIn injection m the treatment of spasmodic torticollis Neurology 19B9.39(1) BO-B4
  10. Iankovic J, Schwartz K Botulmum tOX111 111Jectl0l1S for cervical dystoma Neurology 1990,40(2) 277-280
  11. Blitzer A, Bnn Mr, Keens MS, AV1V JE Botulinum tOX111 for the treatment of hyperfunctional hues of the face Arch Otolaryngol Head Neck Surg 1993,llg(9l1018-1022
  12. 김정택, 함종욱, 최종훈, 김종열 이갈이를 동반한 교근비대증 환자에서 보툴리늄 A형 독소 주사의 효과 경험예 대한치과의사협회지 2003, 41(6) 450-454
  13. fum H], Yam KW, Lee 55, I-leo MS, Seo K Effects of botulmum toxm type A on bilateral mav.ctcnc hypertrophy evaluated With computed Iomom apic management Dermatol Surg 2003,29(5) 484-489
  14. Moore AP, Wood lTD The medical mansgement of masseteric hypertrophy WIth botulmum toxin type A Dr J Oral Maxtllofac Surg 1994.32(1l 26~28
  15. Park MY, AI111 KY, lung DS Botulinum tOXlO tvpe A treatment for contouring of the lower face DermatoJ Surg 2003,29(5) 477~483
  16. Smyth AG Botulmum tOXlO treatment of bilateral massetcnc hypertrophy Br J Oral Maxillofac Surg 1994,32(j) 29~33
  17. Heckmann T\!I, Ceballos-Baumann AO, Plewig C; Botuhnum toxin A for axillary hypertndrosis (excess:ve swealmg) N Engl J Med 200I.:l44 (7) 488-493
  18. Bmder WJ, Bnn MF, BhUeJ' A, Schoenrock LD, Pagoda JM llotulmum toxm type AmOTOX) for treatment of rmgrame headaches, an open- label study Otolaryngol Head Neck Surg 2000,123(6) 009-{)76
  19. Schulte' Maul er WJ. WI"",r T. Zierz S Treatment of tension- type headache with botuhnum toxm a pIlot study Eur J Med Res 1999.4(51U>1-186
  20. Silberstein S. Mathew N. Saper J. Jenkins S Botulinum toxm type A as a rrugrane prcvenuve treatmen t For the IlOTOX Migramc Chrncal Research Group Headache 2000.40(6)445-450
  21. Mohl NV, Lund JP. WIdmer CG. McCall WV Jr Devices for the diagnosis and treatment of temporomandibular disorders Part Il Electromyography and sonography J Prosthet Dent 1990.63(3) 332-336
  22. Moyer RE Temporomandibular muscle contraction patterns In Angle class II diVISIOn 1 malocclusion An electromyographrc study Am J Orthcd Dentofac Orthop 1949.3.1 836-842
  23. Sheikholeslarn A, Moller E. Lous 1 Postural and maximal acuvny in elevators of mandible before and after treatment of functional disorders Scand J Dent Res 1982,900 ) 37-46
  24. Manns A. Miralles R. Santander II. Valdivia J Influence of the vertical dimension In the treatment of rnyofascial pam dysfunction syndrome J Piosthet Dent 1003.50(5) 700-709
  25. Ingervall B. Carlsson GE Masucatory muscle acnvity before and after ehmmanon of balancmg SIde occlusal Interference J Oral Rehabll 1982.9(3) IK!· 92
  26. Chnstcnsen LV. Donegan SJ Observations 10 the ume and frequency domains of surface electromyograms of experimental bncf teeth clenchma 10 man J Oral Rehalnl 1990.17(5) 473-486
  27. Holmgren K, Sherkhokslam A, Ruse C, Kopp S The effects of an occlusal sphnt on the clcct romyographtc acuvines of the temporal and masseter muscles dunng maximal clenching m patients WIth a habit of nocturnal bruxism and SIgns and symptoms of craruornandibular disorder, J Oral Rchsbil 1990,17(5)447-459
  28. Kawazoe Y. Kotam H. Hamada T Relation between integrated clcctrornyograpluc activity and bitmg force durmg voluntary isomctnc contraction In human rnasucatory muscle; J Dent Res 1979.08(5) 1440- 1449
  29. Uchida S. Inoue H. Maeda T Electromyographic study of the actrvny of Jaw depressor muscles before mmation of operung movements J Oral Rehal»l 1999.26(6) 503-510
  30. Kawazoe Y. Kota ra II, Hamada T, Yamada S Effect of occlusal splints on the clcctromyographrc activities of masseter muscles during maximum clenching 11 patients With mvofasctal pam dysfunction syndrome J Prosthet Dent 19800'13(5) 378-500
  31. Mirallos R, Mendoza C. Santander H. Zuruga C. Moya H Influence of stabihzauon oclusal splints on stemocleidomastoid and masseter electrornyograoluc acuvny Cramo 1992.10(4) 297-304
  32. 송창권, 한경수, 정찬 두부자세에 따른 두경부 근활성 및 교합접촉 양태의 변화 대한구강내과학회지 1996, 21(1) 89-101.
  33. Moller E. Sheikholeslam A. Lous I Response of elevator activity during masucauon to treatment of Iunctional disorders. Scand J Vent Res 1984.92(1) 64·83
  34. 허문일, 한경수 저작운동시 전측두근과 교근의 근활성 및 활성시기에 관한 연구 대한구강내과학회지 1999, 24(4) 421-437.
  35. Rugh JD. Harlan J Nocturnal bruxism and temporomandibular disorders Adv Neurol 1988.49 329 -:141
  36. Clark GT. Bccmsterboer PL. Rugh JV Nocturnal masseter muscle activity and the symptoms of masticatory dysfunction J Oral ltehabrl 1981.8(3) 279- 2ffi
  37. Christensen LV. Facial pain and the Jaw muscles a rev iew J Oral Rehabd 1981.8(3) 193-201
  38. Duchen LW An electron microscope study of the changes induced by botuhnum toxin In the motor cnd plate, of slow and fast skeletal muscle fibers of the mouse J Ncurol SCI 1971.14(]) 47-60
  39. Hold' JR. Alderson K. Fogg SG. Anderson RL Motor nerve sprouting In human orbiculans muscle after botulinum A rmccuon Invest Ophthalrnol VIS SCI l!ro.31(5) 964-967
  40. Nramtu J 3rd Aesthetic uses of botuhnum toxm A J Oral Maxillofac Surg 1999,570 Q) 1228-IZJ3
  41. Scott All. Suzuki V Svsterruc tOXICIty of botuhnum toxm by intramuscular nu ection In the monkey Mov Disord 1988.:l(4J:l33·:l.'J5
  42. Borodic GE, Ferrante R, Pearce LR. South K Histologic assessment of dose- related diffusion and muscle fiber response after thcrapeutn, botulinum A toxin uu ecuons Mov Drsord 1994.9(1) 31-39
  43. Park TS. Park j s, KO MY A Chrucal Effect of Botuhnum toxin for the Treatment of Chrome Masticatory Muscle Pam. 대한구강내과학회지 2003;28(1) 77-89
  44. von Lmdem 11. Niederhagen B. Appel T. Berge S. Reich RH Type A botulinum tOXIn for the treatment of hypertrophy of the masseter and temporal muscles an alternative treatment Plast Reconstr Surg 2001.107(2) 327-332
  45. 13mz T, Bias' 1. Yamasaki S. Baumeister A. Lmk E. Sudhof TC, jahn R, Niemann H Proteolysis of SNAP-25 by tyPL'S E and A botulinal neurotoxins 1 13101 Chern 1994.269(3) 1617-1620
  46. Turton K, Chaddock l A, Acharya KR I30tuhnum and tetanus neurotoxms structure, function andtherapeutic utility Trends Biochern ScJ m2,270l) 552-E68
  47. Ellis DA, Tan AK Cosrretic upper- facial rejuvenation WIth botuhnum 1 Otolaryngol 1997.26(2) 92-96